Viral pre-challenge increases central nervous system inflammation after intracranial interleukin-1β injection by unknown
JOURNAL OF 
NEUROINFLAMMATION
Couch et al. Journal of Neuroinflammation 2014, 11:178
http://www.jneuroinflammation.com/content/11/1/178RESEARCH Open AccessViral pre-challenge increases central nervous
system inflammation after intracranial
interleukin-1β injection
Yvonne Couch†, Andrew E Davis†, Inês Sá-Pereira, Sandra J Campbell and Daniel C Anthony*Abstract
Introduction: Systemic inflammation has been shown to significantly worsen the outcome of neurological disease.
However, after acute injuries to the brain both pre- and post-conditioning with bacterial endotoxin has been shown
to reduce leukocyte recruitment to the CNS. Here, we sought to determine whether viral pre-challenge would have
an effect on the outcome of acute CNS inflammation that was distinct from endotoxin.
Methods: Animals received a single intracranial microinjection of IL-1β in the presence or absence of a viral
pre-challenge 24 hours prior to surgery. Liver and brain tissue were analysed for chemokine expression by qRT-PCR and
leukocyte and monocyte infiltration 12 hours, 3 days and 7 days after the IL-1β injection.
Results: Here, a single injection of adenovirus prior to IL-1β injection resulted in adhesion molecule expression,
chemokine expression and the recruitment of neutrophils to the injured CNS in significantly higher numbers than
in IL-1β injected animals. The distribution and persistence of leukocytes within the CNS was also greater after
pre-challenge, with neutrophils being found in both the ipsilateral and contralateral hemispheres. Thus, despite the
absence of virus within the CNS, the presence of virus within the periphery was sufficient to exacerbate CNS disease.
Conclusions: These data suggest that the effect of a peripheral inflammatory challenge on the outcome of CNS injury
or disease is not generic and will be highly dependent on the nature of the pathogen.
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Systemic infections are known to be associated with the
exacerbation of central nervous system (CNS) patho-
logies such as multiple sclerosis (MS) [1], stroke [2],
Parkinson’s and Alzheimer’s diseases [3-5]. Experimen-
tally, there is also evidence to suggest that the combi-
nation of an infection model with, for example, murine
prion disease [6], or with the middle cerebral artery oc-
clusion model of ischemia [7], will exacerbate the CNS
pathology. We have shown that bidirectional communi-
cation between the brain and the peripheral immune
system revolves around the hepatic production of cyto-
kines and chemokines. Moreover, that concomitant
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unless otherwise stated.response (APR) have the potential to interfere with the
immune response to acute brain injury [8,9]. An in-
creased hepatic APR to brain injury and disease would
suggest that any factors that exacerbate the systemic in-
flammatory response are likely to adversely affect disease
outcome [1,10-12].
We have shown that the administration of individual
exogenous APRs, such as CCL-2, will exacerbate a brain
injury model. However, it is clear that the situation is con-
siderably more complicated. Pre- and post-conditioning
studies suggest that stimulating the immune system can
confer a degree of tolerance to CNS injury. In animal
models of stroke, a number of different strategies,
including brief periods of ischemia, afford a degree of
neuroprotection against a subsequent insult [13-15].
Surprisingly, the systemic administration of bacterial lipo-
polysaccharides (LPS) has been reported to confer neuro-
protection from a subsequent ischemic challenge [16,17].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tegies might include the activation of the hypothalamic-
pituitary-adrenal axis, or a form of tachyphylaxis, it is
harder to explain how protective post-conditioning is
achieved. We have shown that pre-conditioning and post-
conditioning using LPS in models of both brain and spinal
cord injury using intracranial IL-1β and spinal cord com-
pression, shows reduced CNS immune activation and
improved outcome [18]. In the latter we found it was pos-
sible to inhibit the recruitment of leukocytes into the
spinal cord after injury using an intravenous injection of
LPS before, and, importantly, after, the compression in-
jury. The peripheral administration of IL-1 [18] did not
have the same effect, suggesting an important role for
toll-like receptor (TLR) signalling pathways. However,
hitherto, it remains unclear whether or not other TLR
pathway activating pathogens, such as viruses, might have
similar LPS-like pre-conditioning effects. Currently, ap-
proximately one third of MS relapses are preceded by a
viral infection, and the rate of relapse appears to be two to
three fold higher following viral infection [19-23]. Thus, it
might be predicted that viral infections should cause ex-
acerbation of CNS lesions. However, the same association
is true for bacterial infections where respiratory and urin-
ary tracts caused by bacteria also appear to trigger relapse
in 20 to 30% of MS patients [22,24]. Activation of innate
immunity by adenoviruses has been reported to occur
through both TLR-dependent and TLR-independent path-
ways, but adenoviruses seem to activate the innate im-
mune system principally via TLR signalling pathways [25].
Given how widespread adenovirus use has become, here
we sought to investigate how pre-challenge with a dsDNA
(double stranded DNA) virus might affect the patho-
genesis of an acute sterile CNS inflammatory lesion.
Subjects and methods
Animals
Adult 8-week-old (200 g), male Wistar rats (Harlan,
Bicester, UK) were housed in specific pathogen-free (SPF)
facilities under a standard light/dark cycle with food and
water ad libitum. In each experiment, at least three ani-
mals were used per treatment group and per time point.
All procedures were carried out in accordance with the
UK Animals (Scientific Procedures) Act, 1986 and with
approval of local and European ethical committees, and
all reasonable efforts were made to minimise discomfort.
Animals were randomly assigned to experimental, groups
as per the ARRIVE guidelines [26].
Pre-challenge and intrastriatal injection of IL-1β
Animals were anaesthetised with 2 to 3% isoflurane in
oxygen. All surgical procedures were performed under an
operating microscope (Wild M650, Leica, Milton Keynes,
UK). Stereotaxic surgery was performed as describedpreviously [27]. Briefly, the head of the anaesthetised
animal was shaved and held in a stereotaxic frame (Kopf
Instruments, Tajunga, California). The skull was then
exposed with a midline sagittal incision and dental burr
drill was used to make a small hole for the injection (co-
ordinates from bregma: A/Pr +1.2 mm, M/L +3.0 mm,
D/V −4.5 mm). One microlitre of rrIL-1β (recombinant
rodent-IL-1β; National Institute for Biological Standards
and Control (NISBC), Potters Bar, UK; 1 μg/μl) or vehicle
(0.9% saline) was microinjected into the left striatum
through a pulled glass microcapillary needle (tip <50 μm),
as our standard laboratory model of brain inflammation
[28]. The cytokine was delivered over a period of 2 minutes
and the micropipette was then left in place for a further
5 minutes to allow the injected cytokine to diffuse away
from the injection site and prevent reflux up the injection
tract. Local anaesthetics were applied to wound sites prior
to recovery. Body temperature was maintained on a
heated blanket throughout the period of anaesthesia and
the animals were allowed to recover in a heated chamber
thereafter. For pre-challenge studies, animals were briefly
anaesthetised using 2% isoflurane via a nose-cone and
injected intravenously with either a luciferase-expressing
adenovirus (AdLuc kindly provided by Prof. Len Seymour,
Oxford) or vehicle (0.9% saline) 24 hours prior to stereo-
taxic surgery. Virus was injected intravenously (iv) at a
concentration of 5 × 109 pfu (plaque-forming unit)/
animal.
Tissue preparation
Animals were surgically anaesthetised and blood was
collected via cardiac puncture into EDTA-coated tubes
(Teklab, Durham, UK), or into serum separators (Southern
Syringe Services Ltd, London, UK). Animals were then
transcardially perfused with 0.9% saline containing 5,000
U/l heparin followed by a periodate lysine paraformalde-
hyde solution (PLP: 2% paraformaldehyde, lysine, perio-
date and 0.05% glutaraldehyde). Tissues were removed,
post-fixed in PLP for 4 hours and further fixed in 30%
sucrose for >12 hours. Ten-micron-thick sections were cut
on a cryostat (Leica, Bucks, UK) and mounted on gelatine-
coated slides. One-microlitre volumes of whole blood were
taken from the EDTA coated tubes and films were pro-
duced on clean glass slides. Blood films were allowed to
dry at room temperature for 5 minutes before being stored
at −20°C.
Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [29]. Briefly, tissue sections were quenched for
endogenous peroxidase activity in alcoholic hydrogen
peroxide (H2O2) solution (0.03% H2O2 in methanol).
Using the Shandon-Sequenza system, non-specific Fc-
dependent binding was blocked with 10% normal serum
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raised) and primary antibody incubation took place. These
included anti-neutrophil serum (HB-199, made in house;
1:10,000, 2 hours at room temperature); anti-ED-1 (mouse
monoclonal, AbD Serotec, Oxford, UK; 1:200 overnight at
room temperature); anti-ICAM-1 (mouse monoclonal, BD
Pharmingen, Oxford, UK; 1:50, 2 hours at room
temperature); anti-luciferase (goat polyclonal, Promega,
Southampton, UK; 1:1,000 overnight at room tem-
perature) and anti-CD11b (OX-42 clone, Serotec, Oxford,
UK; 1:200 overnight at room temperature). Sections were
then incubated with the appropriate biotinylated secon-
dary antibody (Vector Laboratories, Peterborough, UK)
before an avidin-biotin-peroxidase solution (Vectastain
Elite ABC, Vector Laboratories, Peterborough, UK) was
added. Peroxidase labelling was visualised by exposure
to the chromogen diaminobenzidine hydrochloride
(0.5 μg/ml) in 0.1 M phosphate buffer (0.05% H2O2) for
varying times until optimal contrast was achieved. To
control for endogenous biotin present in the liver, a se-
parate avidin-biotin blocking procedure using an avidin-
biotin blocking kit (Vector Laboratories, Peterborough,
UK) was employed. For CNS tissue, samples were taken
serially through the injection site. For blood counts,
smears of 1 μl of blood were taken in triplicate and
stained as above. For each analysis, four representative
fields were chosen for quantitation and the average
number of positive cells was calculated and expressed as
number of cells per mm2. Tissue sections were counter-
stained with cresyl violet and immuno-positive labelling
was quantitated only when associated with a cell nu-
cleus. Spatial maps of positive immunoreactivity were
created using plate 15 from the rat brain atlas [29]. Spe-
cifically, the sections were viewed at 1.6 magnification
using a microscope attached to a camera lucida; positive
staining was dotted onto white paper using a black
marker pen. Images were scanned and superimposed
onto plate 15 of the rat brain atlas to form spatial maps
of overall immunoreactivity. All immunohistochemistry
was performed blind, as per ARRIVE guidelines [26].
Quantitative RT-PCR
One cubic millimetre punches of striatal tissue at the
level of the injection were removed for RNA extraction.
RT-PCR assays were performed as previously described
[30]. Samples were run against absolute copy number
standard curves generated from serially diluted cDNA
from LPS-challenged rat liver. Primer and probe sets for
rat IL-1β, CXCL-1, CCL-2, CXCL-10, CCL-3 (MIP-1α),
and CCL-4 (MIP-1β) were designed using the Roche
universal probe library assay design centre (Roche.com).
Samples were analysed using a Roche Light Cycler 480®
(Roche Diagnostics, Welwyn Garden City, UK) and all
reagents were used according to manufacturer'sinstructions. Briefly, gene-specific primers were com-
bined with a FAM/TAMRA labelled hybridisation probe
(for sequences see Additional file 1: Table S1). PCR was
run according to standard conditions [31]. Analysis was
performed using the Pfaffle method, taking the standard
curve to determine reaction efficiency followed by a
comparative-cycle-threshold method. Results are ex-
pressed as absolute copy number.Statistics
Data are presented as mean ± standard error of the
mean (SEM) for a minimum of three animals at each
time point. Data were analysed using Student's t-test
and two-way ANOVA with Bonferroni-Dunn post hoc
testing for multiple groups where appropriate. Results
were considered statistically significant when P <0.05 as
compared to vehicle-treated or naïve controls where
appropriate.Results
Chemokine expression in the CNS is selectively affected
by viral pre-challenge
In keeping with previous observations, the microinjec-
tion of IL-1β into the brain caused an up-regulation of
cytokines and chemokines known to be involved in
leukocyte migration and recruitment (CXCL-1, IL-1β,
and CCL-3) at 12 hours post-injection (Additional file 2:
Figure S1). The microinjection of IL-1β did not induce
the expression of TNF in the brain (data not shown),
which, while surprising, supports previously reported
findings [32]. While cytokine and chemokine expression
profiles were examined at all time points, significant dif-
ferences in expression were found between vehicle/IL-1β
and AdLuc/IL-1β at 3 days post-injection (Figure 1). At
this time point the microinjection of IL-1β into the brain
had caused an elevation in mRNA for CXCL-1, CCL-2,
IL-1β and CCL-3 relative to naïve levels (Figure 1).
However, the presence of the viral load caused an up-
regulation in CXCL-1, CCL-4 and CXCL-10 production
following the microinjection of IL-1β when compared to
vehicle/IL-1β injection alone (Figure 1). It was of note
that the microinjection of vehicle, in the presence of
AdLuc also induced an up-regulation in CXCL-10 pro-
duction in the brain. By 7 days, only CCL-2 and CXCL-1
remained elevated in all IL-1β injected animals (with
virus or without) compared to naïve or AdLuc/saline-
injected animals (Additional file 3: Figure S2); at this
time none of the other chemokine mRNA species mea-
sured in the CNS were elevated above naïve levels. It is
important to note that immunohistochemistry for lu-
ciferase revealed the presence of luciferase protein in the
liver, but not in the brain of the challenged animals










































































































































































Figure 1 Viral pre-challenge selectively increases chemokine mRNA expression in the brain 3 days following the microinjection of
IL-1β. The microinjection of IL-1β into the brain caused changes in absolute gene copies of mRNA for (A) CXCL-1; (B) CCL-2; (C) CXCL-10;
(D) IL-1β; (E) CCL-3 and (F) CCL-4. Intravenous injections are indicated by italic text. Results are expressed as mean ± SEM (n =3), *P <0.05.
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neutrophils to the blood and to the liver in response to
intrastriatal IL-1β injection
The microinjection of IL-1β into the brain induced a rapid
leukocytosis. Levels of circulating neutrophils rose rapidly,
peaked at 12 hours, and had fallen by 3 days, although at
this time they were still slightly above baseline. Levels did
not change between 3 days and 7 days. When the micro-
injection of IL-1β was preceded by intravenous challenge
with AdLuc, the number circulating neutrophils was
markedly increased at 12 hours (P <0.001). By 3 days,
levels had fallen again and were comparable to the
vehicle/IL-1β group at this time. Neutrophil numbers
again remained stable between 3 days and 7 days, mar-
ginally above baseline. The microinjection of vehicle into
the brain, in the presence of intravenous AdLuc, did not
induce the mobilisation of neutrophils to the blood above
baseline levels (Figure 2A). Twelve hours after the micro-
injection of IL-1β, preceded by challenge with AdLuc, the
numbers of neutrophils (P <0.05) present in the liver wereA
B
Figure 2 Viral pre-challenge increases the acute mobilisation of neutr
Neutrophils immunohistochemically assessed in (A) whole blood and (B) li
the presence of intravenous vehicle (solid line) or AdLuc (5 × 109 CFU - das
the brain, in the presence of intravenous AdLuc. Intravenous injections are
***P <0.001. CFU, colony-forming unit.significantly increased (P <0.05, Figure 2B), which is indi-
cative of an altered APR. That neutrophils were still
present in elevated numbers at 3 days (P <0.05) in the
presence of AdLuc (P <0.001, Figure 2B) is also indicative
of a prolonged APR. When animals were microinjected
with vehicle into the brain, in the presence of intravenous
AdLuc, no elevation of neutrophil numbers above baseline
were observed in the liver (Figure 2B). Despite the ob-
served increases in leukocyte number in the livers of ani-
mals receiving the combined challenge (AdLuc/IL-1β), no
increase in chemokine expression caused by the presence
of the virus was observed. However, it is of note that
CCL-3 and CCL-4 mRNA was significantly up-regulated
in all the animals that received the virus (Additional file 5:
Figure S4).
Adhesion molecule expression is increased in the CNS in
response to viral pre-challenge
The microinjection of vehicle, in the presence of intra-
venous AdLuc, did not cause any observable changes inophils in response to the microinjection of IL-1β into the brain.
ver 12 hours, 3 days or 7 days following IL-1β challenge to the brain in
hed line). Dotted line represents animals microinjected with saline into
indicated by italic text. Results are expressed as mean ± SEM (n =3),
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served in naïve animals (Figure 3A and B). As expected,
the microinjection of IL-1β into the brain induced wide-
spread up-regulation of ICAM-1 expression (Figure 3C)
that was most prominent around vessels actively involved
in recruitment of leukocytes to the injected striatum.
Some staining was also evident, to a lesser extent, in the
cortex in the ipsilateral hemisphere. When animals were
microinjected with IL-1β into the brain, in the presence of
intravenous AdLuc, the up-regulation in ICAM-1 expres-
sion appeared more widespread (Figure 3D). Again, the
strongest ICAM-1 positivity was observed in the ip-
silateral hemisphere, with further up-regulation above
naïve in other areas actively involved in recruitment. The
most notable observation was that in the striatum pre-
conditioned IL-1β animals there appeared to be two
populations of ICAM-1+ vessels. There were small vessels
positive for ICAM-1, but not actively involved in recruit-
ment (arrowhead, Figure 3D), and those heavily positive
for ICAM-1, and cuffed by large numbers of neutrophils
(arrow, and inset, Figure 3D).
Leukocyte recruitment to the IL-1β-challenged brain is
enhanced by viral pre-challenge
The microinjection of IL-1β into the brain in the pre-
sence of intravenous vehicle resulted in elevated num-
bers of neutrophils present in the ipsilateral hemisphere
from 12 hours post-injection (Figure 1A). By 3 days, theA
C
Figure 3 Viral pre-challenge increases the expression of ICAM-1 in th
ICAM-1 expression after the microinjection of vehicle, in the presence of intra
of ICAM-1 expression, which was most evident around vessels actively involve
microinjected with IL-1β, in the presence of intravenous AdLuc (5 × 109 CFU),
subtypes of vessels; smaller vessels not actively involved in recruitment (arrow
the ones where cuffs of neutrophils could be seen (inset). Counterstain is cresnumber of neutrophils had dropped to approximately
35% of those seen at 12 hours, and by 7 days had re-
duced to baseline. The presence of intravenous AdLuc
administered 24 hours prior to the microinjection of
IL-1β caused an elevation in the numbers of neutrophils
observed in the injected hemisphere at 12 hours as com-
pared to vehicle (P <0.01), which persisted to 3 days
post-injection. At this time, neutrophils were presents in
large cuffs around vessels in the injected striatum in ani-
mals receiving AdLuc that was not evident in other
groups (Figure 4A, arrowheads). By 7 days, neutrophil
numbers were for the most part back to baseline, al-
though slightly more were observed in animals that re-
ceived AdLuc, than the IL-1β alone group. In animals
microinjected with vehicle into the brain, in the presence
of intravenous AdLuc, no measurable numbers of neu-
trophils were observed in the brain at any time point
studied. The microinjection of IL-1β into the brain in
the presence of intravenous vehicle also resulted in some
recruitment of neutrophils to the contralateral hemi-
sphere 12 hours after the striatal injection, although at
a much lower level than in the injected hemisphere
(Figure 4A). These were mainly observable in the cortex,
and very few were present in the striatum. By 3 days, the
numbers of neutrophils had returned to baseline levels.
The presence of AdLuc administered 24 hours prior to
the microinjection of IL-1β caused an elevation in the
numbers of neutrophils observed in the contralateralB
D
e brain. Baseline ICAM-1 expression (A) did not differ significantly from
venous AdLuc (B). Intrastriatal IL-1β induced a generalised up-regulation
d in recruitment of leukocytes (C, arrowhead). In the brains of animals
this up-regulation was more notable still (D). Note the two distinct
head) and larger vessels showing increased ICAM-1 positivity, which were
yl violet. Scale bars represent 50 μm. CFU, colony-forming unit.
AB
Figure 4 Viral pre-challenge increases the recruitment of neutrophils and ED-1-positive macrophages to the IL-1β-challenged brain.
Graphs show numbers of neutrophils (A) and ED-1-positive cells (B) in the ipsilateral and contralateral hemisphere at 12 hours, 3 days and 7 days
after the microinjection of IL-1β, in the presence of intravenous vehicle (solid lines) or AdLuc (5 × 109 CFU - dashed lines). Animals microinjected
with vehicle into the brain, in the presence of intravenous AdLuc are shown by dotted line (not visible in (A) due to low constitutive neutrophil
numbers). Immuno-positive neutrophils (A - arrowheads) and ED-1-positive macrophages (B - arrows) are shown in brown. Intravenous injections
are indicated by italic text. Counterstain is cresyl violet. Scale bar represents 50 μm. Results are expressed as mean ± SEM (n =3). Statistical significance
is indicated by **P <0.01, ***P <0.001 respectively. CFU, colony-forming unit.
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neutrophils were again back to baseline.
The microinjection of IL-1β into the brain, in the pre-
sence of intravenous vehicle, also elevated the number of
ED-1-positive cells present in the ipsilateral hemisphere
from 12 hours to 7 days (Figure 4B). The number peaked
at 3 days, but remained well above baseline until day 7.
The presence of intravenous AdLuc administered 24 hours
prior to the microinjection of IL-1β caused a further
significant elevation in the numbers of ED-1-positive cells
all time points. In the contralateral hemisphere, there was
a small increase in the number of ED1-positive cells at
12 hours (P <0.05). By 3 days, the number of ED1 cells
was slighted elevated over baseline, but similar in all the
treatment groups.
Viral pre-challenge alters the temporal profile of
leukocyte recruitment to the IL-1β-challenged brain
In order to better represent the pattern of recruited leu-
kocytes into the CNS, spatial maps were created to show
the patterns and density of cellular recruitment over
time. When animals were microinjected with vehicle, in
the presence of intravenous AdLuc, no neutrophils were
observed in the brain at any time point (Figure 5, leftFigure 5 Viral challenge increases temporal pattern of recruitment of
Illustrations show schematic representations of the pattern of neutrophil recru
the brain for all animals and time points). The microinjection of vehicle, in the
of neutrophils to the brain at any time point (left column). The microinjection
bilateral meningitis, and the recruitment of neutrophils to the injected hemisp
neutrophil recruitment was occurring, and the numbers recruited were de
microinjection of IL-1β was combined with intravenous challenge with Ad
both hemispheres at 12 hours post-injection, with significantly more cells
3 days, the area over which neutrophil recruitment was occurring was red
vehicle. By 7 days, recruitment was near basal levels, although some meni
text. CFU, colony-forming unit.column). The microinjection of IL-1β in the presence of
intravenous vehicle caused large numbers of neutrophils
to be observed in the ipsilateral striatum and cortex at
12 hours (Figure 5, middle column). Limited numbers of
neutrophils were observed in the contralateral cortex,
and bilateral meningitis was present. By 3 days, signifi-
cant numbers of neutrophils remained present in the
injected striatum, but there was much less recruitment
occurring in the cortex, and only isolated cells were ob-
served in the contralateral hemisphere. At this time
point, the meningitis was dramatically reduced in both
spread and magnitude, being largely ipsilateral in nature.
By 7 days, only isolated cells were observable in the
injected striatum, the rest of the brain resembled naïve
tissue. When the microinjection of IL-1β was combined
with intravenous administration of AdLuc 24 hours be-
forehand, the numbers of neutrophils observed in the
brain at 12 hours post-IL-1β was significantly increased
(Figure 5, right column). Within the injected hemi-
sphere, there were no dramatic changes in the manner
of recruitment observed, merely that the vessels actively
engaged in recruitment was spread over a larger area,
contributing to the increase in numbers. The most
striking changes were observed in the contralateralneutrophils to the inflamed central nervous system (CNS).
itment to the challenged brain (* represents the microinjection site in
presence of intravenous AdLuc (5 × 109 CFU) did not cause recruitment
of IL-1β in the presence of intravenous vehicle (central column) caused
here in large numbers at 12 hours. By 3 days, the area over which
creased. By 7 days, only isolated cells were observable. When the
Luc (right column), neutrophil recruitment was widespread, covering
recruited in the contralateral hemisphere than after IL-1β/vehicle. By
uced, although again greater than in animals receiving intravenous
ngitis was still evident. Intravenous injections are indicated by italic
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was occurring was much more widespread within the
cortex, and to a lesser extent, within the striatum. By
3 days, a similar pattern was observed to that seen in
animals injected with IL-β alone, but with some spatial
differences. The area over which recruitment was occur-
ring in the injected hemisphere was much larger, pre-
dominantly in the cortex. Furthermore, in the injected
striatum, large numbers of neutrophils were cuffed
around vessels, five to seven cells thick, indicating that
the process of diapedesis was occurring to a much
greater extent than in the IL-1β/vehicle group. By 7 days,
the differences between the groups were less defined. In
the group administered AdLuc there were marginally
elevated numbers of neutrophils in the injected striatum,
and there was still evidence of meningitis, although the
majority of the section was devoid of neutrophils.
Discussion
In contrast to our previous pre-conditioning studies using
LPS [18], pre-challenge with the AdLuc adenovirus caused
an extended CNS inflammatory response that was charac-
terised by increased leukocyte recruitment lasting until
7 days post-injection, and this response was accompanied
by an increase in adhesion molecule, cytokine, and che-
mokine expression within the ipsilateral hemisphere.
These data suggest that the anti-inflammatory effect of
the conditioning stimulus seen previously appears to be
restricted to endotoxin-specific pathways and suggests
that the systemic administration of AdLuc is likely to have
an adverse effect on the outcome of co-morbid CNS in-
flammatory disease.
The ability of pre-conditioning stimuli to abrogate the
deleterious effects of a systemic inflammatory response on
the outcome of CNS injury is well documented. However,
there are obvious shortcomings in terms of implementing
protective pre-conditioning strategies, and, not least,
among these there is the absence of a complete mecha-
nistic understanding. Here, we have shown that the out-
come of pre-conditioning strategy is highly dependent on
the nature of the pre-conditioning challenge. As in pre-
viously studies [33], we found that AdLuc administered iv
is not detectable in the brain (Additional file 4: Figure S3).
It was considered important to show that the injection of
virus did not result in any infection of CNS cell popula-
tions, which might provoke a local immune response and
confound results. The peripheral iv injection of a replica-
tion deficient adenovirus expressing the NF-κB super-
repressor or luciferase does not result in the expression of
transcript in the brain [33] and here we show that the
luciferase protein is only expressed in the liver. Others
have shown that adenoviruses administered intravenously
preferentially target the liver [34,35]. We found that this
targeting of the liver resulted in a marked elevation in theproduction of mRNA for the related macrophage che-
mokines CCL-3 and CCL-4 in the liver (Additional file 5:
Figure S4), irrespective of the challenge to the CNS. It
should be noted that at 24 hours the luciferase reporter
gene expression would not be expected to generate an im-
munological response per se and it is reasonable to as-
sume that the chemokine response can be attributed to
the vector. The host response to infection with adenoviral
vectors (AdLuc) is known to result in the rapid activation
of innate immunity, which stimulates inflammatory anti-
viral host defenses [36]. CCL-3 and CCL-4 are known to
be involved in responses to certain viral infections [37],
but, in addition to macrophage activation, they can drive
cell proliferation and may encourage viral propagation
such as in Epstein-Barr B-cell infection [38].
In the brain, the microinjection of IL-1β resulted in
the recruitment of neutrophils and ED-1-positive macro-
phages to the ipsilateral hemisphere. Based on observa-
tions from our earlier LPS studies [18], this result was
initially surprising. However, systemic infection is known
to exacerbate inflammatory responses in the brain in
many contexts [39,40] and the result with endotoxin
was the more surprising. This provides a potentially
useful tool to discover the mechanisms that lead to the
viral exacerbation of CNS lesions, such as those occur-
ring in MS, where epidemiological evidence has long
suggested a role for virus infection in the initiation and/
or exacerbation of the disease [41,42]. Theiler's murine
encephalomyelitis virus (TMEV)-induced demyelinating
disease has been used as a model for MS. TMEV-
infected mice develop a demyelinating disease, which,
eventually, is associated with development of myelin-
specific T-cell responses. Viruses have been suggested
to initiate autoimmune disease through bystander activa-
tion of immune cells or through bystander damage to
tissue during infection. In this model, administration of
antiserum to IFN-beta or poly(I:C), a TLR3 agonist mim-
icking a dsRNA viral infection, leads to more severe
demyelinating disease by promoting ‘virus-like’ activity,
specifically the recruitment and activation of ‘bystander’
immune cells within the tissue such as microglia and as-
trocytes [43]. It is interesting to note that this TLR3
pathway, activated by poly(I:C), also exacerbates CNS in-
flammation in a similar manner to our AdLuc TLR9 (and
likely others) agonist. Others have also used poly(I:C) to
investigate how systemic infection might contribute to the
later development of Alzheimer disease and have shown
the development of Alzheimer’s-like pathology following
poly(I:C) exposure prenatally [44].
The observation that AdLuc pre-challenge increased the
numbers of neutrophils present in the IL-1β-challenged
brain for as long as 3 days following surgery is striking.
Whilst limited infiltration of neutrophils may have a pro-
tective role following traumatic injury, elevated neutrophil
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upon ischemic lesions in the brain, and furthermore, re-
cent studies have implied a causative role for neutrophils
in cortical injury [45]. Whilst the current study does not
examine ischemic lesions, the implications for increased
neutrophil recruitment over time are similar. With this in
mind, we were interested to discover if there were any on-
going mechanisms in the brain, which could account for
the increased cellular recruitment observed following
AdLuc challenge. Elevated expression of ICAM-1 was
found in animals microinjected with IL-1β, and further in-
creased by the presence of AdLuc. Constitutive expression
of ICAM-1 in the brain is known to be low, and the ad-
ministration of AdLuc in conjunction with the microinjec-
tion of vehicle did not up-regulate expression in the brain.
This suggests that the virus does not increase adhesion
molecule expression per se, but it appears that the effects
of virus and the microinjection of IL-1β act synergistically
to enhance endothelial signals for recruitment of leuko-
cytes. We have previously shown that blocking adhesion
molecule expression significantly reduces neutrophil infil-
tration into the brain after an IL-1β injection [46] and sug-
gest a similar mechanism may be tested in this system in
order to determine the degree to which these molecules
influence neutrophil trafficking across the endothelium.
Finally, the elevated ED-1-positive macrophage numbers
in the brain following the microinjection of IL-1β was also
an unusual observation. These effects were still evident
7 days following the IL-1β microinjection and the num-
bers were larger than we would ordinarily have expected
considering that we understand leukocyte recruitment to
be restricted primarily to neutrophils following the micro-
injection of IL-1β [47]. When the profile of chemokine
expression in the brain was examined following IL-1β
challenge, it was evident that the presence of AdLuc
caused an up-regulation in the local production of not just
CXCL-1, which we would expect to account for the ele-
vated neutrophil numbers. Indeed, elevations in CCL-2
are known to mobilise monocytes to the injured CNS
[31], but we also observed elevations in the production of
CCL-3, CCL-4 and CXCL-10. CCL-3 and CCL-4 are
known to be produced by glial cells within the CNS and
have been shown to mobilise leukocytes to sites of injury
within the CNS [48]. It seems feasible that the elevation
in beta-chemokine production is responsible for the
increased numbers of ED-1-positive cells observed. How-
ever, while astrocytes do produce chemokine it is im-
portant to note that macrophages/microglia also produce
beta-chemokine and the increased levels of expression
may reflect a downstream consequence of the increased
number of ED-1 cells present following the viral challenge.
For example, IL-1β induces CXCL-10 in astrocytes in cul-
ture [49], but it is also expressed by macrophages and has
been shown to exacerbate experimental autoimmuneencephalomyelitis [50]. CXCL-10 is reported to have a
diverse set of effects in the CNS; it seems to be impor-
tant for the clearance of virus within the CNS [51] but
also induces significant free radical production and
apoptosis [52].
In summary, we have shown that a systemic viral chal-
lenge causes increased recruitment of leukocytes to the
site of IL-1β microinjection in the brain, and also to the
liver. In comparison to our previous work with LPS [18],
these data suggest that viral pre-challenge has delete-
rious effects on the outcome of CNS injury. When con-
sidered in context, viral infection should be considered a
significant risk factor for worsened outcome following
injuries to the CNS, and may also contribute to multi-
organ dysfunction.Additional files
Additional file 1: Table S1. Primer and probe sequences for real-time
polymerase chain reaction.
Additional file 2: Figure S1. Viral pre-conditioning selectively increases
chemokine expression in the brain 12 hours following the microinjection
of IL-1β. The microinjection of IL-1β into the brain caused changes in
absolute gene copies of mRNA for (A) CXCL-1; (B) CCL-2; (C) CXCL-10;
(D) IL-1β; (E) CCL-3 and (F) CCL-4. Intravenous injections are indicated by
italic text. Results are expressed as mean ± SEM (n =3), *P <0.05.
Additional file 3: Figure S2. Viral pre-conditioning selectively increases
chemokine expression in the brain 7 days following the microinjection of
IL-1β. The microinjection of IL-1β into the brain caused changes in
absolute gene copies of mRNA for (A) CXCL-1; (B) CCL-2; (C) CXCL-10;
(D) IL-1β; (E) CCL-3 and (F) CCL-4. Intravenous injections are indicated by
italic text. Results are expressed as mean ± SEM (n =3), *P < 0.05.
Additional file 4: Figure S3. AdLuc administered intravenously does
not enter the brain. Micrographs illustrate representative sections of
(A) brain, and (B) liver of animals administered AdLuc intravenously. In all
treatment groups receiving intravenous AdLuc, no immuno-labelling for
luciferase was observed in the brain at any time point, despite the
microinjection of vehicle or IL-1β into the brain, but was clearly observed
in the liver (B) of the same animals. Immuno-positivity for luciferase
shown in brown (arrows). Scale bars represent 50 μm.
Additional file 5: Figure S4. Viral pre-conditioning causes selective
up-regulation of macrophage-specific chemokines in the liver, irrespective
of the challenge to the brain. The microinjection of IL-1β into the brain
did not alter naïve chemokine mRNA levels in the liver 3 days later. A
pre-challenge with AdLuc caused significant increases in both (A) CCL-3
and (B) CCL-4, irrespective of the challenge into the brain. Intravenous
injections are indicated by italic text. Results are expressed as mean ±
SEM (n =3), *P <0.05.Abbreviations
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